Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Cash Flow (2020 - 2025)

Apellis Pharmaceuticals has reported Net Cash Flow over the past 6 years, most recently at -$13.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$13.0 million for Q4 2025, down 184.91% from a year ago — trailing twelve months through Dec 2025 was $53.9 million (down 11.6% YoY), and the annual figure for FY2025 was $53.9 million, down 11.6%.
  • Net Cash Flow for Q4 2025 was -$13.0 million at Apellis Pharmaceuticals, down from $109.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for APLS hit a ceiling of $356.4 million in Q4 2021 and a floor of -$298.4 million in Q1 2021.
  • Median Net Cash Flow over the past 5 years was -$9.9 million (2022), compared with a mean of -$4.9 million.
  • Peak annual rise in Net Cash Flow hit 3233.39% in 2023, while the deepest fall reached 717.05% in 2023.
  • Apellis Pharmaceuticals' Net Cash Flow stood at $356.4 million in 2021, then tumbled by 109.14% to -$32.6 million in 2022, then tumbled by 212.59% to -$101.8 million in 2023, then soared by 115.07% to $15.3 million in 2024, then plummeted by 184.91% to -$13.0 million in 2025.
  • The last three reported values for Net Cash Flow were -$13.0 million (Q4 2025), $109.1 million (Q3 2025), and $11.0 million (Q2 2025) per Business Quant data.